|

Advances in Imaging to Assess Response in Rectal Cancer

RECRUITINGSponsored by NHS Greater Glasgow and Clyde
Actively Recruiting
SponsorNHS Greater Glasgow and Clyde
Started2024-11-11
Est. completion2026-06-26
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this observational study is to determine the feasibility of acquiring serial MRI images for advanced radiotherapy planning in colorectal patients. The main question it aims to answer: Is it feasible to acquire serial MR images for advanced radiotherapy planning for rectal cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed rectal adenocarcinoma.
* T stage 3b or above and/or high risk factors eg. EMVI, nodal disease.
* Participant able to give written informed consent.
* Male or non-pregnant female ≥18 years of age.
* Scheduled to undergo radical radiotherapy.
* Patients willing and able to comply with the protocol for the duration of study.

Exclusion Criteria:

* Contra-indications to MRI, such as claustrophobia, excessive body weight, MRI unsafe implants, ferrous metal in the body, insufficient information on prior surgeries. MRI conditional implants where conditions cannot be met (e.g pacemakers).
* Any previous radiotherapy to the pelvis.
* Inflammatory bowel disease.
* Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating clinician.
* History of physical or psychiatric disorder that would prevent informed consent and compliance with the protocol.
* Patients with de-functioning stoma.
* Major surgery within 28 days prior to trial entry.

Conditions2

CancerColorectal Cancer (CRC)

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.